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In Haiti, 22 communes still require mass drug administration (MDA) to eliminate lymphatic
filariasis (LF) as a public health problem. Several clinical trials have shown that a single oral
dose of ivermectin (IVM), diethylcarbamazine (DEC) and albendazole (ALB) (IDA) is more
effective than DEC plus ALB (DA) for clearing Wuchereria bancrofti microfilariae (Mf). We
performed a cluster-randomized community study to compare the safety and efficacy of IDA
and DA in an LF-endemic area in northern Haiti. Ten localities were randomized to receive
either DA or IDA. Participants were monitored for adverse events (AE), parasite antigene-
mia, and microfilaremia. Antigen-positive participants were retested one year after MDA to
assess treatment efficacy. Fewer participants (11.0%, 321/2917) experienced at least one
AE after IDA compared to DA (17.3%, 491/2844, P<0.001). Most AEs were mild, and the
three most common AEs reported were headaches, dizziness and abdominal pain. Serious
AEs developed in three participants who received DA. Baseline prevalence for filarial antige-
nemia was 8.0% (239/3004) in IDA localities and 11.5% (344/2994) in DA localities
(<0.001). Of those with positive antigenemia, 17.6% (42/239) in IDA localities and 20.9%
(72/344, P = 0.25) in DA localities were microfilaremic. One year after treatment, 84% per-
cent of persons with positive filarial antigen tests at baseline could be retested. Clearance
rates for filarial antigenemia were 20.5% (41/200) after IDA versus 25.4% (74/289) after DA
(P = 0.3). However, 94.4% (34/36) of IDA recipients and 75.9% (44/58) of DA recipients with
baseline microfilaremia were Mf negative at the time of retest (P = 0.02). Thus, MDA with
IDA was at least as well tolerated and significantly more effective for clearing Mf compared
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to the standard DA regimen in this study. Effective MDA coverage with IDA could accelerate
the elimination of LF as a public health problem in the 22 communes that still require MDA in
Haiti.
Author summary
Lymphatic filariasis (LF) also known as “elephantiasis” is caused by infection with filarial
worms that are transmitted by mosquitoes. The Global Programme to Eliminate LF
(GPELF) aims to interrupt disease transmission through annual rounds of mass drug
administration (MDA). Several studies have shown that a single dose of a triple-drug ther-
apy (ivermectin, diethylcarbamazine and albendazole or IDA) was superior to a single
dose of the standard double-drug therapy (diethylcarbamazine and albendazole or DA)
and might accelerate LF elimination. In Northern Haiti, we performed a large community
treatment study to compare the safety and efficacy of three-drug and two-drug therapies.
Almost 6,000 participants were treated with IDA or DA and tested for LF. Each partici-
pant was assessed for adverse events (AE) and participants who tested positive for LF at
enrollment were retested one year after treatment. Less participants who received IDA
(11.0%) experienced AEs compared to participants who received DA (17.3%). IDA was
also more effective to eliminate microfilariae (adult worm offspring) from the blood com-
pare to DA. Results from this study showed that IDA was well tolerated in Haiti and has
the potential to accelerate LF elimination in countries that currently use DA if high MDA
coverage can be achieved.
Introduction
Lymphatic filariasis (LF) is a vector-borne neglected tropical disease caused by the nematode
parasites Wuchereria bancrofti, Brugia malayi and B. timori [1]. Adult filariae cause severe
damage to the lymphatic system leading to chronic, disabling morbidities such as lymph-
edema, elephantiasis, and hydrocele. The World Health Assembly passed Resolution 50.29 in
1997 that called for elimination of LF as a public health problem [2]. Consequently, the World
Health Organization (WHO) launched the Global Programme to Eliminate Lymphatic Filaria-
sis (GPELF) in 2000. To interrupt transmission, WHO recommends community distribution
of antifilarial medications to entire at-risk populations through community-based mass drug
administration (MDA). Ivermectin (IVM) and albendazole (ALB) are provided as MDA in
areas where onchocerciasis is co-endemic with LF; diethylcarbamazine (DEC) and ALB are
provided in areas without onchocerciasis or loiasis [3].
The WHO recommends at least five years of annual MDA with effective coverage (with at
least 65% of the total population swallowing the medicines) before performing surveys to
assess whether MDA can be stopped [4]. In 2018, 52 of the 76 countries endemic for LF still
required MDA. Of those, three countries had not started MDA and 11 countries had not
implemented MDAs in all endemic districts. Additionally, in some countries that have
achieved at least five years of effective MDAs, surveys have indicated that the criteria for stop-
ping MDA have not been met [5]. Therefore, the objective of eliminating LF as a public health
problem globally by 2020 will not be achieved using the standard 2-drug MDA regimens.
Several clinical trials have shown that a 3-drug regimen (IVM, DEC and ALB or IDA) is
superior to the currently recommended 2-drug regimen (DEC and ALB or DA) for clearing
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microfilaremia [6–8]. Post-treatment systemic adverse events (AE) were commonly reported
after both treatments but were more frequently reported after IDA than after DA. However,
no serious AE (SAE) were observed among people taking IDA. The dramatic reduction and
sustained clearance of microfilaremia along with the safety profiles seen in these studies sug-
gested that the 3-drug regimen may be a useful tool for accelerating the path towards elimina-
tion of LF as a public health problem [9].
Although these studies clearly demonstrated the superiority of IDA for clearing W. ban-
crofti microfilariae (Mf) from the blood, additional supportive safety and efficacy data were
needed before this triple therapy could be recommended for large scale use as an MDA regi-
men in LF endemic countries. WHO recommends a best practice called “cohort event moni-
toring” for demonstrating safety of new drug regimens for public health program use [10].
Cohort event monitoring refers to the use of prospective, observational cohort studies of
patients to whom the medicine of interest has been administered. It avoids some of the com-
mon deficiencies in drug safety assessment studies such as incomplete reporting, absence of
denominators, and investigator biases. The term adverse event refers to an undesirable experi-
ence after treatment without regard to whether it is or is not treatment related. A cohort of
10,000 patients is sufficient to provide adequate statistical power to detect serious AEs that
occur at a rate equal to or greater than 0.1% [11].
Haiti is one of four countries in the Americas where transmission of LF still occurs [5]. In
2001, a national survey undertaken by the Ministère de la Santé Publique et de la Population
(MSPP) and partners indicated that approximately 90% of Haiti’s 140 communes (equivalent
to districts) required MDA; this corresponded to an at-risk population of nearly 8 million peo-
ple. Haiti follows the WHO’s LF elimination strategy by providing annual MDA with DEC
and ALB for a minimum of five years. Even though LF was not identified in every commune,
all communes were targeted for MDA. MDA was provided in one commune in 2000, and
MSSP achieved full geographic coverage with MDA in 2012 [12, 13]. By 2019, 87% (122/140)
of communes in Haiti no longer required MDA. Despite these successes, a persistent challenge
has been continued LF transmission, even after 10 years of MDA, in several communes that
had high baseline LF prevalence (10−45% antigenemia) [14]. The increased efficacy of IDA
represents an opportunity to address this challenge.
To meet the WHO requirement of establishing the safety of IDA MDA in at least 10,000
people, community safety studies were conducted with IDA and DA for cohort event monitor-
ing in five countries (Haiti, Indonesia, India, Fiji and Papua New Guinea) with different LF
species and mosquito vectors [15]. Here we report detailed results from the Haiti study. The
primary objective was to compare the frequency, type and severity of AEs following MDA
with IDA versus DA in infected and uninfected individuals. A secondary objective of the study
was to compare the efficacy of the two regimens for clearing microfilaremia and filarial antige-
nemia as assessed one year after treatment.
Methods
Ethics statement
Ethical approval for the study was granted by the National Bioethics Committee (1718–11) of
the Ministry of Public Health and Population (MSPP) of Haiti. All participants aged 18 years
and older provided written informed consent before any study procedures were done. Partici-
pation of children (7−17 years of age) required their written assent and the written permission
of one parent or guardian; participation of children 5–6 years of age only required permission
from one parent or guardian. If a participant was unable to read or write, another literate per-
son who was not involved in the study (family member, neighbor or other community
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member) could act as a witness to the consenting process. A copy of the information sheet and
the signed consent/assent form with a phone contact number was given to each participant.
Study setting
The study was conducted between October 31, 2016 and February 10, 2017 in 10 localities of
the Commune of Quartier Morin (19.6967 N, -72.1586 W) located in the Northern Depart-
ment of Haiti (Fig 1). A “commune” is the third-level geographic division in Haiti (equivalent
to a district in many other countries), and a “locality” is equivalent to a sub-district. The base-
line antigenemia prevalence in the commune of Quartier Morin was high, estimated at 39%
in 2001. WHO recommends that to stop MDA, microfilaremia or antigenemia prevalence
should be under pre-determined thresholds of<1% or<2%, respectively. A survey among
residents> 5 years of age performed in 2014 after seven consecutive annual rounds of MDA
found that the prevalence of LF was still too high to stop MDA in the Commune of Quartier
Morin. The filarial antigenemia prevalence was 4.2% (21/496) and 38% of those with antigene-
mia were Mf positive (eight positives, 1.6% of all persons tested). Some of the localities
Fig 1. Localities randomly assigned to treatment regimen (DA or IDA) and position of houses included in the 2016 census. DA, diethylcarbamazine
plus albendazole; IDA, ivermectin plus diethylcarbamazine and albendazole.
https://doi.org/10.1371/journal.pntd.0008298.g001
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included in the current study are communities that were surveyed in 2014. In July 2016, in prep-
aration for the present study, a census enumerated a total of 12,383 people living in 2,669 house-
holds in the 10 localities of the Quartier Morin commune selected for the study (Fig 1). Females
comprised 53.4% of residents, and 8.2% of residents were younger than five years of age.
Study design and enrollment of participants
We used an open-label, cluster-randomized community study design to study the relative
safety and efficacy of IDA vs. DA in the 10 localities mentioned above. Each locality was ran-
domly assigned to receive either the IDA regimen consisting of a single dose of IVM (200 μg/
kg) + DEC (6 mg/kg) + ALB (400 mg) (5 communities) or the DA regimen consisting of a sin-
gle dose of DEC (6 mg/kg) +ALB (400 mg) (5 communities) (Fig 1). All eligible residents of
the 10 localities were invited to participate in the study. Eligible residents were�5 years old,
were able to provide consent (or assent plus parental consent for minors), had no history of
allergy to the study medications, and were not pregnant or suffering from severe chronic ill-
nesses. Women who reported that their last menstrual period started�4 weeks before enroll-
ment or who did not recall the date of their last menstrual period were excluded. The core
study team, assisted by community health workers who had participated in prior rounds of
MDA, visited each house included in the July 2016 census to enrol participants.
Procedures
After consenting and prior to evaluation for LF infection and treatment, participants were
enrolled and assigned a unique identification number. Four trained enrollment teams weighed
and measured the height of each participant and recorded their age, sex, general health status
and (for females) date of last menstrual period. Then, the enrollment nurse asked each partici-
pant about symptoms that corresponded to each of the AEs that were to be assessed after the
treatment to establish a baseline.
Laboratory technicians tested each participant for circulating filarial antigenemia (CFA)
using the Alere Filariasis Test Strip (FTS, Alere) performed according to the manufacturer’s
instructions. Capillary blood (75μl) was placed on the sample application pad and the result
was read at 10 minutes. Since the intensity of antigen test lines is correlated with CFA levels,
the results were scored as previously described [16, 17]: 0 for tests with no visible test (T) line;
1 when the T line was weaker than the control (C) line; 2 when the T line was approximately as
dark as the C line; and 3 when the T line was darker than the C line. FTS positive participants
were tested for microfilaremia at night (from 10 pm−12 am) by thick blood smear examina-
tion. Three parallel lines of blood (20 μl each) were placed on slides. Dried slides were stained
with Giemsa and examined by trained microscopists.
A dosing table was used to determine the number of IVM (200 μg /kg) and DEC (6mg/kg)
tablets for each participant based on their weight. ALB was provided at a fixed dose of 400 mg.
Treatment was directly observed to ensure that all enrolled individuals swallowed the tablets.
Doses vomited shortly after administration were replaced. If the FTS was positive, the treat-
ment was administered at night after blood was collected for Mf testing.
Safety study
Adverse events (AE) were defined as any unfavorable and unintended abnormal laboratory
finding, symptom or disease that occurred during the study, regardless of whether it was
related to the intervention. AEs were classified as mild (grade 1), moderate (grade 2), severe
(grade 3), life-threatening (grade 4) and death (grade 5) according to a modified grading sys-
tem based on the Common Terminology Criteria for Adverse Events (CTCAE) from National
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Cancer Institute [18]. Serious AEs (SAEs) were defined as any AE that resulted in any of the fol-
lowing outcomes: death, life-threatening event (immediate risk of death), hospitalization or pro-
longation of existing hospitalization, persistent or significant disability or incapacity, or
congenital anomaly/birth defect. In addition, other important medical events could be judged
to be a SAE if, based upon appropriate medical judgment, the event was believed to jeopardize
the participant or require medical or surgical intervention to prevent one of the outcomes listed
above. The relationship between each reported or observed SAE and the study medications was
investigated and judged by a medical officer to be definitely, probably, possibly, unlikely, or
unrelated to treatment. Nurses and physicians collected AE information in an electronic case
report form (eCRF). An initial period of active monitoring required a daily house visit by a
nurse during the two days following treatment (day 1−2 of follow up). Participants who devel-
oped AEs during the next five days (day 3−7, passive follow up) were asked to either contact a
study nurse who was in their area or call a hotline monitored by a study staff member and avail-
able 24 hours a day and seven days a week. Any AE greater than grade 2 was evaluated by a
medical officer who had received specific training for the study. The medical officer on duty
completed an AE Evaluation and Report Form for any grade 3, 4 or 5 AE and for all participants
who required overnight hospitalization. The physician provided any required immediate treat-
ment and facilitated admission into a local hospital as deemed appropriate. Participants with
AEs greater than grade 2 were seen daily by a physician or a nurse until their symptoms
resolved. Assessment and management of AEs was free of charge for all participants.
Efficacy study
The objective of the efficacy study was to assess responses to treatment and to compare the effi-
cacy of the two treatment regimens for clearing microfilaremia and CFA. Therefore, partici-
pants who were positive for CFA (FTS) at baseline were retested one year after treatment for
CFA and microfilaremia as described above.
Data acquisition, transfer, and management
An electronic data capture (EDC) system developed by CliniOps (Fremont, CA, USA) was
used to compile the data into two databases: baseline and efficacy. Deidentified data were
entered directly into a tablet via a mobile data management application called CliniTrial. The
data were entered by a designated trained member of each survey team on the day of enroll-
ment, AE assessment, or at the 1-year follow up. The EDC system is 21 CFR Part 11 compliant.
eCRFs were developed to comply with International Council for Harmonization on Good
Clinical Practice (ICH GCP) and Clinical Data Acquisition Standards Harmonization / Clini-
cal Data Interchange Standards Consortium (CDASH/CDISC) standards [19]. User accept-
ability testing was performed for eCRFs prior to their deployment. Validation checks and
automated alert checks were programmed into the EDC system to maintain a high level of
data quality at point of entry. Data were synchronized regularly through a secured server. AEs
were coded using MedDRA dictionaries (version 20.0) [20]. Paper CRFs were used for backup
in case of EDC or equipment malfunction and for documentation of SAEs. All written forms
(i.e., consent and backup data collection forms) were stored at the endemic country collabora-
tor’s institution as per in-country institutional review board (IRB) requirements for storage of
source documents.
Sample size and statistical analysis
The WHO requires a total of 10,000 participants to detect with high confidence a SAE rate of
less than 0.1%. In Haiti, we aimed to enroll 3,000 participants per drug regimen to make a
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substantial contribution to the global, multi-site sample size, which was reached by including
participants in Haiti and in the four other countries.
Data were analyzed with SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). Baseline
characteristics of the cohort including CFA and Mf positivity were compared between study
arms using chi-square tests and Wilcoxon rank sum tests as appropriate. At baseline, the pro-
portion of FTS and Mf positivity was compared by sex, age, and locality using chi-square tests.
The primary objective for the safety study was to document the rate of AEs that occurred
among participants within the first seven days post treatment (day 1−7) by treatment group.
This was calculated by dividing the number of participants with at least one AE by the number
of participants assessed. The AE outcome (measured at the individual level) was an AE of any
severity during the 7-day follow up period. We analyzed this dichotomous outcome using a
generalized linear mixed model (GLMM) that assumed a binomial distribution and a logit link
function. Locality was treated as a random effect to account for correlation among participants
within localities. The association between drug treatment (IDA vs DA) and AEs was assessed
using both a univariable logit model and a multivariable logit model where we adjusted the
treatment effect for the following covariates: age group (< 18 years and� 18 years), sex, and
Mf and CFA positivity.
The objective of the efficacy study was to compare changes among CFA positive partici-
pants at baseline in CFA and Mf prevalence one year after treatment both overall and by study
regimen using chi squared tests. Among CFA positives, the proportions of participants in each
FTS score category (1–3) and the proportions of participants Mf positive participants were
compared between baseline and 1-year follow-up using chi squared tests. Among Mf positives,
the geometric mean Mf counts per 1 mL of blood were compared at baseline and at follow up
using a test on log-transformed values. Among CFA and Mf positive participants at baseline,
we compared the rate of conversion to negative status at 12-month follow-up by treatment reg-
imen. P-values < 0.05 were considered statistically significant.
Results
Enrollment and baseline results
In the 10 localities, 6,494 people agreed to participate in the study, which represented 52.4%
(6,494/12,383) of the census population. Of these, 5,998 (92.4%) were eligible and included in
the safety study. Based on random assignment of localities to drug regimens, 3,004 participants
from five localities received IDA and 2994 participants from the five remaining localities
received DA (Fig 2). Thus 48.4% (5,998/12,383) of the population enumerated in the census
received treatment: 47.3% (3,004/6,355) in the localities receiving IDA and 49.7% (2,994/
6,028) in the localities receiving DA (Fig 2). The inclusion rates by locality ranged from 39.5%
to 64.9%. Because the arrival of ivermectin tablets in Haiti was delayed, the study teams first
enrolled people living in the localities assigned to DA.
Baseline demographic and filarial infection data are provided in Table 1. The median age of
participants was 18 years in the IDA and DA groups (P = 0.2). Similar proportions of female
participants were included in the DA and IDA groups (52.8% vs 53.5%, P = 0.5). The CFA
prevalence was 9.7% (583/5,993, 95% confidence interval [CI] = 9.0–10.5%) and the Mf preva-
lence was 1.9% (114/5,987, 95% CI = 1.6–2.3%). The geometric mean Mf count for those with
microfilaremia was 250/mL (range 17–8,567). More participants included in the DA treatment
area were antigen-positive compared to the DA area (11.5% vs. 8.0%, P< 0.01). Similarly,
more participants in the DA treatment area were Mf positive compared to the DA area (2.4%
vs. 1.4%, P = 0.004). Most of the CFA positive participants in both treatment areas had strongly
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positive FTS results (scores of 3) at baseline (Table 1). Mf prevalence at baseline in persons
with FTS scores of 1, 2, or 3 were 2.8%, 6.7%, and 38.1%, respectively.
Before treatment, more men than women were CFA and Mf positive in both treatment
groups, and prevalence by Mf and CFA was significantly higher in older participants (Table 2
and Fig 3). Compared to the July 2016 census, the enrolled study population had a similar sex
distribution (46.8% male in study compared to 45.9% male in census); however, older age
groups (who were more likely to be CFA or Mf positive) were under-sampled among both
sexes (Fig 4). When adjusted for age and gender by population weights, the CFA prevalence
was 11.1% overall (95% CI = 10.2–11.9%), 14.6% in males (95% CI = 13.2–16.1%) and 8.0% in
females (95% CI = 7.0–9.0%). Similarly, the age corrected Mf prevalence at baseline was 2.3%
overall (95% CI = 1.9–2.7%), 3.8% in males (95% CI = 3.0–4.6%) and 1.0% in females (95%
CI = 0.6–1.4%). The infection rate also varied by locality (Table 2). The proportion of partici-
pants with positive FTS results ranged from 4.6% (53/1,148, 95% CI: 3.4%–5.8%) in Balan to
16.0% (16/100, 95% CI: 8.8%23.2%) in Lazarre; the proportion of participants with microfilare-
mia ranged from 0.4% (5/1,148, 95% CI: 0.1%-0.8%) in Balan to 3.8% (41/1,082, 95% CI: 2.8%-
5.1%) in Galman.
Safety study results
For the safety study, 96.0% (5761/5998) of participants treated were visited at least once during
the 7-day follow-up period (2917 after IDA and 2844 after DA). During the active follow up,
90.5% (5,430/5,998) of participants were visited during the first day of follow up and 88.5%
(5,311/5998) during the second day; 96.0% (5,758/5,998) were visited on either day and 83.1%
Fig 2. Study diagram for participants included in the safety (solid line) and efficacy study (dash line). DA, diethylcarbamazine plus albendazole; IDA, ivermectin plus
diethylcarbamazine and albendazole; CFA, circulating filarial antigenemia; Mf, microfilariae. Cluster randomization was used for treatment allocation for each locality.
https://doi.org/10.1371/journal.pntd.0008298.g002
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(4,983/5,998) were visited both days. Overall, 14.1% (812/5761) of participants that had AEs
assessed reported at least one AE during the week following treatment. The intracluster corre-
lation coefficient for AE was low (0.02). Unexpectedly, more participants receiving DA
(17.3%, 491/2,844) reported an AE compared to participants who received IDA (11.0%, 321/
2917) (Table 3). Most AEs reported were mild, 88.7% (436/491) of all AEs in the DA arm and
93.4%, (300/321) of all AEs in the IDA arm (Table 3). More women reported AEs than men in
both treatment areas (Table 3). Finally, people� 18 years old reported more AEs (17.9%, 525/
2927) compared to participants <18 years old (10.1%, 287/2834).
No participant experienced a SAE after IDA (0%, 0/2917, 95% CI 0.0–0.1)). Three partici-
pants (0.1%, 3/2,844, 95% CI 0.0–0.3) experienced a SAE after DA (Table 3). The first person
with a SAE was a 78 years old male (CFA positive) who was hospitalized for evaluation of
hypertension, urinary tract infection and anemia. The second SAE was in a 35 years old male
(CFA and Mf positive) who was hospitalized for evaluation of dysuria, nausea, vomiting and
fever. The third person with a SAE was a 13 years old male with acute lower abdominal pain.
His evaluation revealed ascariasis, H. pylori infection. Though AEs in participants with SAEs
were graded no higher than three, these AEs were classified as serious, because participants
were admitted overnight in the hospital ward for evaluation and observation for at least 24
hours. All three SAEs resolved within 48 hours. Two of the SAEs were considered by attending
Table 1. Baseline demographic characteristics and infection status of participants by treatment area at enrollment, October 2016−February 2017.
Total n (%) IDA n (%) DA n (%) P value�
Demographics
Female 3,189 (53.2) 1,609 (53.5) 1,580 (52.8) 0.5
Male 2,809 (46.8) 1,395 (45.4) 1,414 (47.2) -
Age
median (range)1 18 (5–97) 18 (5–95) 18 (5–97) 0.2
5–9 years 1,200 (20.0) 592 (19.7) 608 (20.3) 0.04
10–19 years 2,032 (33.9) 1,067 (35.5) 965 (32.2) -
20–29 years 1,217 (20.3) 601 (20.0) 616 (20.6) -
30–39 years 727 (12.1) 354 (11.8) 373 (12.5) -
40–49 years 407 (6.8) 207 (6.9) 200 (6.7) -
50+ years 415 (6.9) 183 (6.1) 232 (7.8) -
Infection Status
CFA positive2 583 (9.7) 239 (8.0) 344 (11.5) <0.001
FTS Score 1# 145 (24.9) 47 (19.7) 98 (28.5) 0.05
FTS Score 2# 180 (30.9) 80 (33.5) 100 (29.1) -
FTS Score 3# 258 (44.2) 112 (46.8) 146 (42.4) -
Mf positive3 114 (1.9) 42 (1.4) 72 (2.4) 0.004
Mf geometric mean1 (Mf /ml) 250 305 217 0.2
Mf range (Mf /ml) 17–8,567 17–5,667 17–8,567 -
Total (N) 5,998 3,004 2,994
�Chi square P value unless otherwise noted
1P value is from T test on transformed values
2N is 5993
3N is 5987
# Percent represent the proportion of positive FTS test by score divided by the total number of positive tests
DA, diethylcarbamazine plus albendazole; IDA, ivermectin plus diethylcarbamazine and albendazole; CFA, circulating filarial antigenemia; Mf, microfilariae; FTS,
Filariasis Test Strip (Alere)
https://doi.org/10.1371/journal.pntd.0008298.t001
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Table 2. Baseline characteristic by infection status, October 2016−February 2017.
CFA positive Mf Positive Total
n (%) P value� n (%) P value�
Total 583 (9.7) 114 (1.9) 5993��
Sex
Female 237 (7.4) <0.001 28 (0.9) <0.001 3,187
Male 346 (12.3) - 86 (3.1) - 2,806
Age in years
Age 5–9 64 (5.3) <0.001 8 (0.7) <0.001 1,200
Age 10–19 103 (5.1) - 14 (0.7) - 2,032
Age 20–29 168 (13.8) - 38 (3.1) - 1,215
Age 30–39 126 (17.4) - 24 (3.3) - 726
Age 40–49 50 (12.3) - 13 (3.2) - 406
Age 50+ 72 (17.4) - 17 (4.1) - 414
Locality (treatment)
Balan (IDA) 53 (4.6) <0.001 5 (0.4) <0.001^ 1,148
Bonnay Dugal (IDA) 27 (7.6) - 6 (1.7) - 357
Bonnay Crayon (IDA) 31 (10.0) - 4 (1.3) - 310
Feve (IDA) 112 (10.3) - 24 (2.2) - 1,088
Lazarre (IDA) 16 (16.0) - 3 (3.0) - 100
Petite Charite (DA) 15 (6.9) - 1 (0.5) - 217
La Rue (DA) 59 (7.2) - 4 (0.5) - 821
Guillaudeaux (DA) 12 (8.8) - 4 (2.9) - 137
Centre Ville (DA) 100 (13.6) - 22 (3.0) - 733
Galman (DA) 158 (14.6) - 41 (3.8) - 1,082
�Chi square P value unless otherwise noted; ^Monte Carlo estimate for Fisher’s exact P value
�� N is 5987 for participants tested for Mf
CFA, circulating filarial antigenemia; Mf, microfilaremia; DA, diethylcarbamazine plus albendazole; IDA, ivermectin plus diethylcarbamazine and albendazole
https://doi.org/10.1371/journal.pntd.0008298.t002
Fig 3. Proportion of participants CFA positive (A) and Mf positive (B) by age-group and sex before receiving treatment (baseline). CFA, circulating filarial
antigenemia; Mf, microfilariae.
https://doi.org/10.1371/journal.pntd.0008298.g003
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physicians to have been possibly related to treatment, and one (the 13 years old male) was con-
sidered to have been probably related to treatment. A more extensive clinical summary of
these SAEs has been published elsewhere [15].
AEs were more frequent following treatment in Mf positive participants but AE rates in
persons with microfilaremia were similar after IDA treatment (34.1%, 14/41) and after DA
treatment (39.4%, 26/66) (Table 4). For persons with microfilaremia, pre-treatment Mf counts
were significantly higher in persons who experienced AEs after treatment compared to persons
who did not experience AEs (geometric means: 20.98 Mf/mL vs. 8.81 Mf/mL, P = 0.002).
A multivariable logistic regression analysis showed that after controlling for age, sex and
infection status, the risk for experiencing an AE was significantly lower for a participant who
received IDA compared to a participant who received DA. Microfilaremia, isolated antigene-
mia (amicrofilaremic), age>18 years, and female sex were also significantly associated with
AEs in the multivariable model (Fig 5).
A total of 1,187 AEs were reported by 812 study participants who reported at least one AE.
The most frequent AEs reported in both treatment areas were headache, abdominal pain and
dizziness. The types and proportions of AEs observed and reported among participants were
similar after DA and IDA treatment (Fig 6). Scrotal (pain or swelling) AEs were reported by
Fig 4. Males (A) and females (B) included in the census who enrolled in the study by age-group.
https://doi.org/10.1371/journal.pntd.0008298.g004
Table 3. Frequency of AEs and maximum AE grade/subject after treatment by type of treatment and gender, October 2016−February 2017.












DA Female 1529 324 (21.2) 289 (18.9) 27 (1.8) 8 (0.5) 0
Male 1315 167 (12.7) 147 (11.2) 16 (1.2) 1 (0.1) 3 (0.2)
Total 2844 491 (17.3) 436 (15.3) 43 (1.5) 9 (0.3) 3 (0.1)
IDA Female 1568 207 (13.2) 197 (12.6) 7 (0.4) 3 (0.2) 0
Male 1349 114 (8.5) 103 (7.6) 10 (0.7) 1 (0.1) 0
Total 2917 321 (11.0) 300 (10.3) 17 (0.6) 4 (0.1) 0
DA, diethylcarbamazine plus albendazole; IDA, ivermectin plus diethylcarbamazine and albendazole; AE, adverse event; SAE, serious adverse event
https://doi.org/10.1371/journal.pntd.0008298.t003
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1.3% (35/2,664) of men. They were more commonly reported after DA (2.1%, 28/1315) than
after IDA (0.5%, 7/1,349) (P = 0.0003) and among Mf positive men (8.6%, 7/81) than among
Mf negative men (1.1%, 28/2549) (P<0.0001). Most scrotal AEs were of severity grade 1 (32/
35, 91.4%). After DA, two men reported grade 2 scrotal AEs and one man reported a grade 3
scrotal AE. All scrotal AEs (7) reported in the IDA treatment group were grade 1.
Efficacy study results
In January 2018, 83.9% (489/583) of participants who were CFA positive at baseline were
retested for the efficacy study. This included 94 participants who were microfilaremic at base-
line. The follow up rates were similar for participants who had been treated with IDA and DA
(Fig 2).
The proportions of participants who were CFA positive at baseline and who became CFA
negative after one year were similar in those who received IDA (20.5%, 41/200) and DA
(25.6%, 74/289) (P = 0.3). The largest proportion of CFA-positive participants received an FTS
score of 3 at baseline, however most participants with persistent CFA had an FTS score of 1
one year after treatment (Fig 7).The proportion of FTS score 1 changed from 19.7% to 47.2%
in the IDA arm (P<0.001) and from 28.5% to 48.9% in the DA arm (P<0.001). When compar-
ing treatment group to each other, there was no statistically significant difference in the distri-
bution of FTS scores between groups at visit 1 (P = 0.5) or visit 2 (P = 0.9).
One year after treatment, significantly more participants who were Mf positive at baseline
became Mf negative after IDA (94.4%, 34/36) compared to after DA (75.9%, 44/58) (P = 0.02).
The two participants who remained Mf positive after IDA had Mf counts of 3,050 Mf/mL and
1383 Mf/mL at baseline. One year after treatment, the Mf counts in both participants were 33/
mL (Fig 8). Two participants who were CFA positive and Mf negative at baseline were Mf posi-
tive one year after DA. The FTS score for both participants was 2 at baseline. One year after
treatment, the FTS score of the first participant was 3 and the Mf count was 6,667 Mf/mL; the
FTS score of the second participant was 1 and the Mf count was 50Mf/mL. Overall, the Mf geo-
metric mean one year after treatment among Mf positive participants at baseline decreased
from 250 Mf/mL to 124 Mf/mL (P = 0.07). The decrease was not significant in the DA arm
(223 Mf/mL vs. 148 Mf/mL, P = 0.3) whereas it was in the IDA arm (305 Mf/mL vs. 33 Mf/mL,
P = 0.04).
Gender was not associated with total clearance of Mf or CFA after either treatment using
chi-squared tests. Younger age was associated with conversion to FTS negativity in participants
after DA but not after IDA. Age was not associated with conversion to Mf negativity (Table 5).
Table 4. Frequency of AEs and maximum AE grade/subject after treatment by type of treatment and Mf status, October 2016–February 2017.












DA Mf (-) 2769 464 (16.8) 415 (15.0) 39 (1.4) 8 (0.3) 2 (0.1)
Mf (+) 66 26 (39.4) 21 (31.8) 3 (4.5) 1 (1.5) 1 (1.5)
Total 2835 490 (17.3) 436 (15.4) 42 (1.5) 9 (0.3) 3 (0.1)
IDA Mf (-) 2875 307 (10.7) 288 (10.0) 15 (0.5) 4 (0.1) 0
Mf (+) 41 14 (34.1) 12 (29.3) 2 (4.9) 0 0
Total 2916 321 (11.0) 300 (10.3) 17 (0.6) 4 (0.1) 0
11 subjects with missing values for Mf and 10 subjects with missing values for Mf and AE
DA, diethylcarbamazine plus albendazole; IDA, ivermectin plus diethylcarbamazine and albendazole; Mf, microfilariae; AE, adverse event; SAE, serious adverse event
https://doi.org/10.1371/journal.pntd.0008298.t004
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Discussion
This cluster-randomized, open-label community study represents the first evaluation of the
safety and efficacy of IDA MDA for LF in Haiti. IDA was well tolerated by the study partici-
pants and was more effective for clearing Mf than DA. Both treatments reduced CFA levels,
but relatively few participants completely cleared CFA after a single dose of either DA or IDA.
The Haiti study was part of a multicenter safety study in five countries that found that IDA
was well tolerated in LF-endemic communities [15]. Haiti was the only country where the pro-
portion of participants with AE was significantly lower in people taking the IDA regimen than
in people taking the DA regimen. Although we do not know with certainty the reason for this,
several factors may have contributed. Localities assigned to receive DA were treated during a
rainy season characterized by heavy floods and long period of rains. This may have led to
increases in vector and non-vector borne infections that were counted as AEs during that
period. Another possible explanation for fewer AEs after IDA might be that the ancillary bene-
fits provided by IVM such as improvement of scabies [21] and strongyloidiasis [22]. These
benefits may have decreased the number of AEs reported by participants who received IDA
compared to those who received DA, because IDA recipients may have experienced an
improvement of symptoms related to these two infections. Additionally, despite random
Fig 5. Forest plot showing adjusted odds ratios for factors associated with adverse events following treatment for lymphatic filariasis.
https://doi.org/10.1371/journal.pntd.0008298.g005
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assignment of localities to the two drug regimens, the proportion of participants who were Mf
or CFA positive at baseline were higher in DA treatment areas than in IDA treatment areas.
However, AE rates in Mf positive participants were not significantly different in the DA and
IDA treatment areas.
Importantly, as was observed in other studies, most AEs reported by participants receiving
IDA were mild. Only three SAE were recorded during the study, all after DA. No SAEs were
recorded after IDA, which gave us confidence that the SAE rate for this study was less than 0.1%
among participants treated with IDA. These AEs were categorized as serious because participants
were admitted to the hospital late in the day and stayed overnight for observation; all three
patients were discharged the next day. While they satisfied the criteria for SAE, the severity of
these events was relatively low (grade 3), and AE durations were short. Regardless of drug regi-
men, the most common AEs reported were headache, dizziness and abdominal pain, which was
similar to those reported by participants in an early study of IDA for LF [7]. These same AEs were
also commonly reported among participants from other countries in the multicenter study [15].
Fig 6. Frequencies of the most commonly observed adverse events (AEs) by type of treatment. Frequencies are expressed as percentages of participants who were
assessed for AEs after treatment.
https://doi.org/10.1371/journal.pntd.0008298.g006
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In our study, where the overall Mf rate at baseline was 1.9%, we found that microfilaremic
participants were more likely to report AEs (37.4%) than amicrofilaremic participants (13.7%).
As opposed to other countries included in the multicenter study, the proportion of
Fig 7. FTS score distribution at baseline and one year after treatment by type of treatment. FTS, Filariasis Test Strip.
https://doi.org/10.1371/journal.pntd.0008298.g007
Fig 8. Microfilaremia reduction 12 months after treatment by type of treatment. DA, diethylcarbamazine plus albendazole; IDA, ivermectin plus
diethylcarbamazine and albendazole; Mf, microfilariae.
https://doi.org/10.1371/journal.pntd.0008298.g008
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microfilaremic patients who experienced at least one AE did not differ significantly between
those who took DA and IDA regimens (Table 4). Previous reports on AEs following single
dose treatment of LF have also showed that the AE rates following DEC or IVM treatment
were typically higher in microfilaremic participants [23]. One safety study carried out in the
commune of Leogane in Haiti after MDA with DEC and ALB reported that in a population
where the Mf prevalence ranged from 1% to 16%, 24% (17,421/71,187) of the population
treated during MDA reported AE [24].
Most previous studies assessing the safety of antifilarial drugs have been carried out in per-
sons with microfilaremia. For example, studies in Papua New Guinea and Ivory Coast that
assessed AEs in persons with high level microfilaremia reported AEs rate of 83% and 100%
respectively among participants who received IDA [7, 8]. A randomized placebo-controlled
study of microfilaremic children in Haiti who took ALB and IVM alone or in combination
found that the most commonly reported AE were fever, headache, myalgias and cough. These
AEs were recorded more frequently for children who had taken IVM alone or in combination
with ALB. Symptom severity was associated with higher Mf counts [25]. Another study in
Haiti compared DEC and IVM for treatment of bancroftian filariasis in microfilaremic adults.
Ninety percent of participants receiving an initial dose (1 mg) of IVM reported at least one
AE, most commonly headache, fever and myalgias. Only participants who received DEC devel-
oped scrotal reactions indicative of death of adult worms [26].
As was observed in other countries participating in this multicenter study, women were
more likely than men and adults were more likely than children to report AEs after adjusting
for infection status. This finding suggests that the observed differences in AE rates in these two
groups are not attributable to differences in infection rates. A review of AE following single
dose treatment of LF reported that of those studies that reported gender-specific AE rates,
most did not find significant differences in AE rates between genders [23]. In Haiti, one study
reported more moderate AEs among men than women following MDA with ALB and DEC
[24]. In that study, 1.5% of males reported localized scrotal reactions severe enough to interfere
with daily activities. This accounted for 40% of all moderate AEs recorded during the study. In
our study, scrotal pain or swelling was reported by 2.1% of men after IDA and by 0.5% of men
after DA.
Table 5. Proportion of CFA and Mf positive participants with negative conversion 12-months after treatment by type of treatment, sex, and age.
IDA DA
CFA (+) to CFA (-)
n (%)
P value� Mf (+) to Mf (-)
n (%)
P value� CFA (+) to CFA (-)
n (%)


























9/27 (33.3) 3/4 (75.0)
18 + 31/145
(21.4)
25/26 (96.2) 50/234 (21.4) 41/54 (75.9)
�Chi squared P value
DA, diethylcarbamazine plus albendazole; IDA, ivermectin plus diethylcarbamazine and albendazole; CFA, circulating filarial antigenemia; Mf, microfilariae
https://doi.org/10.1371/journal.pntd.0008298.t005
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One limitation of this study is that less than half of the population in the initial census
agreed to participate in the study. Considerable effort was undertaken to increase participa-
tion. For example, study teams enrolled participants in the afternoons and evenings to increase
the chance of finding people at home after school or work, community leaders repeated
announcements throughout the study and study teams carried out multiple mop up visits in
each locality. Variable enrollment rates by community illustrate how acceptability of a public
health intervention can vary locally. We noted that the low participation rate in the study was
not related to high baseline infection rates. For example, the locality of Balan had one of the
lowest participation rates (40%) but the CFA and Mf prevalence were the lowest before treat-
ment, 4.6% and 0.4% respectively. Complacency due to many prior rounds of MDA for LF in
this area may have contributed to the low participation rate. Also, proximity to a large town
may have played a role, as many studies have documented higher compliance in rural settings
compared to cities [27–29]. LF elimination programs will need to develop social mobilization
and drug distribution strategies specifically tailored to reach non-adherent populations. This is
particularly relevant for the LF elimination program in Haiti. Transmission assessment surveys
(TAS) or sentinel site surveys have documented LF prevalence above the targets that are
required for stopping MDA after 10 years of MDA in several communes that had high baseline
prevalence. The reasons for this situation are probably multi-factorial (ecological, program-
matic, socio-cultural, epidemiologic). In general, ensuring high MDA coverage in all persons
with LF infection will be critical to elimination regardless of drug regimen used.
Overall, CFA and Mf prevalence in the study areas (IDA and DA) just prior to MDA were
9.7% and 1.9% respectively. Despite the study area being small and localities bordering each
other, infection rates were significantly different in the localities studied. CFA was present in
5.3% of children 5–9 years old; 8 of the CFA positive children were also Mf positive. The base-
line results among children (many of whom were born after years of MDA in the study area)
provide strong evidence for ongoing LF transmission in these communities. This is further
supported by the proportions of adults 20 years old and older who were positive for CFA
(15.0%) and Mf (3.3%). About 45% of the participants who were CFA-positive at baseline had
an FTS score of three; Mf prevalence was higher in persons with high FTS scores. This relation-
ship has been observed in studies conducted in four African countries in areas that had not
previously received MDA [17].
Baseline infection prevalence before MDA and MDA coverage results are reported by com-
mune in Haiti and not by localities. In the commune of Quartier Morin, the infection rate in
2001 was reported to be 39% (CFA among 6–11 years old children) [30] and reported cover-
ages during 2012–2015 were consistently high, around 100%. Coverage surveys (results not
available) have been recently undertaken by the MSPP to validate these results. One wonders
whether the variability in infection prevalence at baseline in this study reflects focality in
parameters such as original pre-MDA infection rates, mosquito factors, or the cumulative
effects of variable MDA compliance and systematic non-adherence related to local factors
[31]. A gender difference in CFA and Mf prevalence at baseline was also observed. This could
be related to differences in exposure to mosquito bites or to lower MDA adherence over years.
Howerver, we observed than fewer older people (who were more likely to have been exposed
to LF) participated in our study but that men and women’s participation was relatively evenly
distributed among different age groups (Fig 4). It is also possible that age-based dosing of DEC
in the national program systematically led to under dosing of males relative to females [32].
More than 80% of the CFA positive participants at baseline were retested one year after
treatment. The change in antigenemia did not differ between arms and about three quarters of
all participants remained CFA positive after one year. However, FTS scores tended to decrease
after treatment. Almost 95% of the participants who were Mf positive at baseline were
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amicrofilaremic one year after receiving IDA compared to 74.9% for participants who received
DA. These results were similar to results found in the clinical trials in Ivory Coast and Papua
New Guinea and confirmed that the 3-drug therapy has dramatic microfilaricidal and steriliz-
ing effect with a partial macrofilaricidal effect [7, 8]. Our results confirm that using CFA to
assess endpoints for MDA after IDA will be challenging. TAS routinely implemented to deter-
mine if MDA can be stopped are implemented in children 6–7 years old using FTS. In our
study, we looked at changes in CFA and Mf prevalence after IDA in children 5–9 years old. In
that age-group, all children became Mf negative one year after treatment, but 80% remained
antigenemic. Persistence of antigenemia was also seen in older people (Table 5). These results
suggest that using the TAS methodology to measure the true impact of the 3-drug regimen
compared to the 2-drug regimen in places that have implemented IDA MDA for one or two
years as recommended by WHO [33] might be challenging since the impact of these two regi-
mens on antigenemia is similar.
Based in part on results from clinical trials and the multicenter safety study [15], WHO
published a guideline in 2017 for alternative MDA regimens to eliminate LF. One special set-
ting in which WHO recommends the use of annual IDA rather than annual DA is in imple-
mentation units (communes in the case of Haiti) that have not met the epidemiological
thresholds in sentinel and spot-check site survey or in TAS despite meeting drug coverage tar-
gets [34]. This is the case for most communes in Haiti where MDAs are still needed. The effi-
cacy results from this study suggest that substitution of IDA for DA may accelerate LF
elimination in Haiti. However, strengthening operational aspects of MDA to ensure high com-
munity compliance (including in previously non-adherent groups) and operational research
to determine the best way to measure the impact of MDAs and endpoints for MDA programs
that use IDA are needed.
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